- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MYKOGREEN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 33,640 | -0,09 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,740 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,900 | 0,00 % | Dyne Therapeutics auf Morgan Stanley Konferenz: Pläne zur Markteinführung im Fokus | ||
| PRAXIS PRECISION MEDICINES | 312,90 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CG ONCOLOGY | 72,55 | 0,00 % | CG Oncology auf Morgan Stanley Konferenz: Pläne für Markteinführung, Daten und Skalierung | ||
| RELAY THERAPEUTICS | 18,970 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 33,150 | 0,00 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| QIAGEN | 37,180 | +1,88 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,910 | 0,00 % | Mineralys auf Wells Fargo Konferenz: Markteinführung von Lorundrostat nimmt Gestalt an | ||
| SUMMIT THERAPEUTICS | 17,405 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| EDGEWISE THERAPEUTICS | 43,630 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,430 | 0,00 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| ERASCA | 16,265 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 20,540 | 0,00 % | BTIG hebt Kursziel für Cullinan Oncology nach Studiendaten an | ||
| VIR BIOTECHNOLOGY | 10,440 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen |
Das Unternehmen MYKOGREEN BIOTECHNOLOGY AG kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MYKOGREEN BIOTECHNOLOGY AG finden Sie auf Wallstreet Online.